tiprankstipranks
Analyst Profile
Followed by 88 other investors
.
Ami Fadia

Ami Fadia

Needham
Wall Street Analyst
Ranked #3,231 out of 8,047 Analysts on TipRanks (#6,696 out of 21,521 overall experts)

Success Rate

47%
81 out of 173 Profitable Transactions

Average Return

2.30%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Ami Fadia's ratings since 2012 and opened each position for the duration of 1 Year:
46.82% of your transactions would have been profitable with an average return of 2.3%

Stock Rating Distribution

313Ratings
67.73% Buy
30.67% Hold
1.60% Sell
Distribution of Ami Fadia's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Jazz Pharmaceuticals
(JAZZ)
Rating Type:Buy
Dates:Feb 27, 2013 - Feb 27, 2014
Gain:188.30%
The most profitable rating made by Ami Fadia

Ami Fadia's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Virtus Cumberland Municipal Bond ETF
Hold
Reiterated
0.00%
1
Cadence Pharma
Hold
Reiterated
0.00%
1
Alkermes
Buy
Reiterated
$37.00
(41.49% Upside)
100%
+26.30%
2
Momenta Pharma
Buy
Upgraded
0%
-1.20%
2
Salix
Hold
Reiterated
0.00%
3
Hospira Inc
Hold
Reiterated
0.00%
4
Auxilium
Hold
Downgraded
100%
+23.13%
5
Horizon Therapeutics
Buy
Reiterated
0%
-50.30%
1
Sucampo Pharmaceuticals
Buy
Initiated
100%
+0.80%
1
Assertio Therapeutics
Hold
Reiterated
$26.00
(584.21% Upside)
100%
+29.97%
7
List of latest recommendations made by Ami Fadia. Click to expand and see Ami Fadia's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More